Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Stock

Equities

BMY

US1101221083

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 02:26:43 2024-06-06 pm EDT 		5-day change 1st Jan Change
40.96 USD -0.69% Intraday chart for Bristol-Myers Squibb Company +1.78% -20.16%
Jun. 05 I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT
Jun. 05 I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers CI

Financials (USD)

Sales 2024 * 46.09B Sales 2025 * 46.06B Capitalization 83.6B
Net income 2024 * -5.41B Net income 2025 * 10.22B EV / Sales 2024 * 2.66 x
Net Debt 2024 * 39.03B Net Debt 2025 * 31.68B EV / Sales 2025 * 2.5 x
P/E ratio 2024 *
-15.7 x
P/E ratio 2025 *
7.8 x
Employees 34,100
Yield 2024 *
5.83%
Yield 2025 *
6.13%
Free-Float 69.27%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients MT
Bristol Myers: positive results in liver cancer CF
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial CI
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company CI
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies MT
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting CI
Bristol Myers: presents advances in lung cancer CF
Bristol Myers Squibb Presents Multiple New Analyses At 2024 Asco® Annual Meeting Highlighting Opdivo and Opdivo-Based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer CI
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes RE
GSK blood cancer drug nearly halves risk of death in late-stage trial RE
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®? CI
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma MT
Bristol Myers: FDA approval for Breyanzi CF
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma AQ
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial BU
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference BU
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting BU
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : résultats positifs dans le cancer du foie
Bristol Myers : présente ses avancées en cancer du poumon
Bristol Myers : approbation de la FDA pour Breyanzi
Bristol Myers : nouvelle approbation de la CE pour Opdivo
Bristol Myers : présentera des données sur la schizophrénie
More news

Quotes and Performance

1 day+0.24%
1 week+2.46%
Current month+0.37%
1 month-6.25%
3 months-20.42%
6 months-17.90%
Current year-19.63%
More quotes

Highs and lows

1 week
40.13
Extreme 40.125
42.39
1 month
39.91
Extreme 39.91
45.72
Current year
39.91
Extreme 39.91
55.04
1 year
39.91
Extreme 39.91
66.38
3 years
39.91
Extreme 39.91
81.44
5 years
39.91
Extreme 39.91
81.44
10 years
39.91
Extreme 39.91
81.44
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19-11-19
Peter Arduini BRD
 Director/Board Member 59 16-03-31
Derica Rice BRD
 Director/Board Member 59 20-08-31
More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
12.97% 254 M€ +13.39% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
4.99% 2 M€ -.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
4.01% 17 M€ +8.17% -
More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date Price Change Volume
24-06-06 40.92 -0.76% 6 109 793
24-06-05 41.24 -1.22% 12,401,151
24-06-04 41.75 -0.05% 12,229,996
24-06-03 41.77 +1.65% 13,678,650
24-05-31 41.09 +2.09% 29,396,257

Delayed Quote Nyse, June 05, 2024 at 04:00 pm EDT

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-06-11 - Goldman Sachs Global Healthcare Conference
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.24 USD
Average target price
53.19 USD
Spread / Average Target
+28.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-19.63% 83.6B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.69% 749B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 605B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.87% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.74% 328B
ABBVIE INC. Stock AbbVie Inc.
+6.76% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.08% 248B
ROCHE HOLDING AG Stock Roche Holding AG
-3.44% 214B
NOVARTIS AG Stock Novartis AG
+11.35% 216B
PFIZER, INC. Stock Pfizer, Inc.
+2.64% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock